Company intelligence / Profile preview

Metro International Biotech

Worcester, Massachusetts, United Statesmetrobiotech.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Metro International Biotech has robust preclinical data supporting the broad therapeutic potential of modulating NAD+. Its lead compound MIB‑626 has completed multiple Phase I trials demonstrating safety and tolerability. Ongoing Phase II studies are targeting COVID‑19, acute kidney injury, mild dementia, and other age-related conditions. The company also has a second clinical candidate in early-stage trials.

Therapeutic areas: NephrologyRare DiseasesOtherNeurologyInfectious Diseases
Modalities: Small molecules (NAD+ precursors/enhancers)
Industry: Biotech

Drug pipeline

2 assets

nicotinamide mononucleotide (Metro International Biotech)

1 more asset in the full pipeline.

Request access →

Partnerships

U.S. Special Operations Command/SOCOM for studies on muscle energetics/human performance

Beyond the preview

Go deeper on Metro International Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metro International Biotech.

Explore the full profile